非经典蛋白激酶C iota及其抑制剂在肿瘤治疗中的研究进展  

Research progress of nonclassical protein kinase C iota and its inhibitors in cancer therapy

作　　者：蒋安蓉 喻玲玲[1,2,3] 邓颖 李澳 JIANG Anrong;YU Lingling;DENG Ying;LI Ao(Medical College of Three Gorges University,Yichang 443002,China;Hubei Key Laboratory of Natural Products Research and Development,Yichang 443002,China;Third-grade Pharmacological Laboratory on Traditional Chinese Medicine Approved by State Administration of Traditional Chinese Medicine,Yichang 443002,China;College of Science and Technology of China Three Gorges University,Yichang 443002,China)

机构地区：[1]三峡大学医学院,宜昌443002 [2]天然产物研究与利用湖北省重点实验室,宜昌443002 [3]国家中医药管理局中药药理(肿瘤)科研三级实验室,宜昌443002 [4]三峡大学科技学院,宜昌443002

出　　处：《生命的化学》2020年第8期1337-1345,共9页Chemistry of Life

基　　金：国家自然科学基金项目(81503355)。

摘　　要：非经典蛋白激酶C iota(protein kinase C iota,PKCι)是非经典蛋白激酶C(atyptical protein kinase C,aPKC)的一个亚型。PKCι具有不同于aPKC家族成员的独特生理功能。作为第一个人致癌基因的PKC激酶,PKCι在肿瘤形成和发生发展、免疫应答等过程中发挥重要作用,其已经成为癌症治疗中一个极具吸引力的靶点。蛋白激酶抑制剂是一类主要的靶向治疗药物,对癌症和其他疾病的治疗均有积极作用。本文主要就近年来PKCι在肿瘤治疗中的作用及PKCι抑制剂的研究进展进行综述,以期为临床应用PKCι选择性抑制剂靶向治疗肿瘤提供理论依据。Atypical protein kinase C iota(protein kinase C iota,PKCι)is a subtype of nonclassical protein kinase C(aPKC).PKCιhas a unique physiological function different from other members of the aPKC family.As the first human oncogene,PKC kinases play an important role in tumor formation,development,and immune response,and have become an attractive target for cancer therapy.Protein kinase inhibitors are a major class of targeted therapies that have a positive effect on the treatment of cancer and other diseases.This review discussed the role of PKCιin tumor treatment and the research progress of PKCιinhibitors in recent years,in order to provide a theoretical basis for the clinical application of PKCιselective inhibitors to target tumors.

关 键 词：PKCι 肿瘤 治疗靶点 抑制剂 

分 类 号：R730.5[医药卫生—肿瘤]